Bausch Health Companies Inc.
BHCHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Oct 26, 2026
Scan Results
Daily timeframeBausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. The $2.41B market capitalization puts BHC squarely in mid-cap range for its industry. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.
Market Cap
$2.41B
Beta
0.37
P/E (TTM)
—
P/E (Fwd)
1.50
EPS (TTM)
$-2.95
EPS (Fwd)
$4.29
ROE
—
ROA
6.6%
Cash
$1.82B
Total Debt
$20.78B
Free CF
$1.43B
52W Change
3.9%
Annual Financials
Cash vs Debt
Where BHC stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, BHC finished 13.46% above its 150-day moving average ($5.57) and 10.30% above its 200-day moving average ($5.73). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BHC overbought or oversold?
At the October 20, 2026 close, BHC's RSI(14) was 70.6, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $1.82B in cash, though total debt stands at $20.78B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $1.43B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. An ROA of 6.6% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $8.12B (2022) to $10.27B (2025), reflecting a 26% increase over the period.
BHC's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BHC.